Nextgen (NXGN) - Total Assets
Based on the latest financial reports, Nextgen (NXGN) holds total assets worth ILA1.48 Million ILA (≈ $3.97K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nextgen - Total Assets Trend (2008–2024)
This chart illustrates how Nextgen's total assets have evolved over time, based on quarterly financial data. Also see NXGN market cap for the company's overall valuation and market capitalisation.
Nextgen - Asset Composition Analysis
Current Asset Composition (December 2024)
Nextgen's total assets of ILA1.48 Million consist of 39.8% current assets and 60.2% non-current assets. Review NXGN liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 8.2% |
| Accounts Receivable | ILA100.00K | 17.4% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Nextgen's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Nextgen for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nextgen's current assets represent 39.8% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 8.2% of total assets in 2024, down from 33.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 77.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 17.4% of total assets.
Nextgen Competitors by Total Assets
Key competitors of Nextgen based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.68 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥1.17 Billion |
|
Embecta Corp
NASDAQ:EMBC
|
USA | $1.27 Billion |
Nextgen - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.16 | 1.56 |
| Quick Ratio | 0.05 | 0.16 | 1.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-10.53 Million | ILA-2.29 Million | ILA435.00K |
Nextgen - Advanced Valuation Insights
This section examines the relationship between Nextgen's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.79 |
| Latest Market Cap to Assets Ratio | 2.29 |
| Asset Growth Rate (YoY) | 120.3% |
| Total Assets | ILA575.00K |
| Market Capitalization | $1.32 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nextgen's assets at a significant premium (2.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Nextgen's assets grew by 120.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nextgen (2008–2024)
The table below shows the annual total assets of Nextgen from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA575.00K ≈ $1.54K |
+120.31% |
| 2023-12-31 | ILA261.00K ≈ $699.73 |
-98.25% |
| 2022-12-31 | ILA14.89 Million ≈ $39.91K |
-36.99% |
| 2021-12-31 | ILA23.63 Million ≈ $63.34K |
+183.98% |
| 2020-12-31 | ILA8.32 Million ≈ $22.31K |
+330.42% |
| 2019-12-31 | ILA1.93 Million ≈ $5.18K |
-38.01% |
| 2018-12-31 | ILA3.12 Million ≈ $8.36K |
-28.34% |
| 2017-12-31 | ILA4.35 Million ≈ $11.66K |
-27.35% |
| 2016-12-31 | ILA5.99 Million ≈ $16.06K |
+142.47% |
| 2015-12-31 | ILA2.47 Million ≈ $6.62K |
-25.69% |
| 2014-12-31 | ILA3.32 Million ≈ $8.91K |
+141.57% |
| 2013-12-31 | ILA1.38 Million ≈ $3.69K |
-44.87% |
| 2012-12-31 | ILA2.50 Million ≈ $6.69K |
-15.04% |
| 2011-12-31 | ILA2.94 Million ≈ $7.88K |
-60.22% |
| 2010-12-31 | ILA7.38 Million ≈ $19.80K |
+46.70% |
| 2008-12-31 | ILA5.03 Million ≈ $13.50K |
-- |
About Nextgen
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.